Canadian Intellectual Property Office grants patent to CardioGenics' QL Care Analyzer

CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) announced today that it has been notified by the Canadian Intellectual Property Office that its patent application for the "core technology" utilized in its ultra-sensitive point-of-care immuno-analyzer, the QL Care™ Analyzer, has been granted. Patents covering the "core technology" have now been issued in Canada, the European Union and Japan. A patent application for the "core technology" is currently pending in the U.S. before the United States Patent & Trademark Office (USPTO).

Yahia Gawad, MD, Chief Executive Officer of CardioGenics Holdings Inc. said, "We are very pleased that the patent offices of Canada, the European Union and Japan have acknowledged the unique nature of the 'core technology' upon which our QL Care™ Analyzer is based."